Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"Any Little Opening": Whistleblowers Target New Kinds Of Pharma Conduct

Executive Summary

Pharmaceutical companies have overhauled their marketing practices but continue to be hit with qui tam suits as whistleblowers come up with new kinds of claims against them.

You may also be interested in...

DoJ Expanding False Claims Cases Into New Areas Left Before To FDA

The Department of Justice is going after pharmaceutical companies for behavior that traditionally has been left to FDA for regulatory enforcement.

Making A Federal Case Of Marketing Abuses: FDA Trains OCI Staff On Developing Cases Worth Prosecuting

FDA is training investigators in its Office of Criminal Investigations on how to pursue cases against individuals for off-label drug promotion so that they are able to convince U.S. Attorneys' Offices to prosecute them.

Former KV Pharmaceutical CEO Sentenced To 30 Days In Jail

Marc Hermelin pleads guilty to distributing oversized morphine sulfate tablets; he may be first pharma exec to be jailed for healthcare fraud.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts